Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
New Stories
-
New deal raises questions over the need for rebate pilot
April 24, 2018 - - Latest News -
Guild: Extend access to flu vaccine
April 24, 2018 - - Latest News -
New research on triple therapy in advance of PBS listing
April 24, 2018 - - Latest News -
Patients to access cancer treatment at home
April 24, 2018 - - Latest News -
AbbVie: Not yet on Venclexta but future is positive
April 23, 2018 - - Latest News -
A proud industry committed to doing the right thing
April 23, 2018 - - Latest News -
March PBAC outcomes
April 23, 2018 - - Latest News